DR DRMA Dermata Therapeutics, Inc. Common Stock Loading... : Investor Sentiment and Bull/Bear Views

The author highlights Dermata Therapeutics as a squeeze candidate with short interest at 3,604.43% of float, an off-exchange short volume ratio of 53.21% and days-to-cover of 8.87. He argues the setup is reinforced by positive Phase 3 results for the acne treatment XYNGARI meeting all primary endpoints, which management says de-risks the second Phase 3 trial and could make it the first once-weekly topical acne treatment. That combination of extreme short positioning and clinical progress is framed as the squeeze catalyst.

The author argues DRMA looks primed for a move because short interest was well above 100% leading into the new year and the January 12 short-interest data drop made it 'an object of power.' The implied mechanism is a short squeeze driven by heavily crowded bearish positioning. No explicit time horizon or risk is stated beyond the 'nfa' disclaimer.

Author claims DRMA has a micro float under one million shares, making it easy to move, and it has ranked top 3 on SqueezeFinder all week. He argues that with downward pressure and pending momentum, the setup is 'free money' for a major move.